| 000 | 01528nam a2200265 4500 | ||
|---|---|---|---|
| 001 | ESSALUD | ||
| 005 | 20260903093950.0 | ||
| 007 | ta | ||
| 008 | t pe ||||| |||| 00| 0 spa d | ||
| 040 | _aBMG | ||
| 041 | _aeng | ||
| 100 |
_aDer, Channing J. _eAutor _954512 |
||
| 245 | _aAdvances in RAS therapeutics for pancreatic cancer | ||
| 300 | _apáginas: 1857-1861 | ||
| 520 | _aSomatic mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) occur in more than 90% of pancreatic ductal adenocarcinomas. In this issue of the Journal, Wolpin et al. evaluated the side-effect profile of and response to a first-in-class small-molecule drug called daraxonrasib, which targets the active state of RAS (see Key Concepts) in patients with metastatic pancreatic ductal adenocarcinoma who have received at least one previous line of chemotherapy. In the context of second-line treatment, they reported an objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, in up to 35% of patients and a median response duration of 8.2 months. | ||
| 650 |
_aCÁNCER _91231 |
||
| 650 |
_aCÁNCER DEL TRACTO GASTROINTESTINAL _953776 |
||
| 650 |
_aGASTROENTEROLOGÍA _912562 |
||
| 650 |
_aHEMATOLOGÍA _97422 |
||
| 650 |
_aONCOLOGÍA _912240 |
||
| 650 |
_aGENÉTICA GENERAL _954107 |
||
| 700 |
_aYeh, Jen Jen _954513 |
||
| 773 | 0 |
_022717 _922676 _dMassachusetts NEJM Group _oNEJM015 _tThe New England Journal of Medicine _wESSALUD _x0028-4793 |
|
| 942 |
_cARTICULOS _e2026-08-31 _zsqb |
||
| 999 |
_c22915 _d22915 |
||